Most Read Articles
01 Apr 2016
Amiodarone is safe and effective for early junctional ectopic tachycardia prophylaxis in paediatric patients following open heart surgery, based on a study.
Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Jairia Dela Cruz, 05 Mar 2018
Abaloparatide appears to produce significant increases in the bone mass density (BMD), as well as nominal reductions in fractures, in very elderly women with osteoporosis, with a safety profile similar to that in the overall study population, according to a posthoc analysis of the phase III ACTIVE trial.

Antibiotic resistance in H. pylori should influence treatment strategy in Asia-Pacific, suggests new study

Roshini Claire Anthony
11 Sep 2017

The increasing resistance to certain antibiotics in Helicobacter pylori (H. pylori) eradication therapies is associated with a reduction in treatment efficacy in Asia-Pacific countries, and treatments should be adapted accordingly, according to a systematic review and meta-analysis.

“The rise in clarithromycin and levofloxacin resistance in the past 25 years in most countries in the Asia-Pacific region is concerning, and this should prompt the development of effective strategies to control antibiotic resistance,” said the researchers led by Dr Kuo Yu-Ting from the National Taiwan University Hospital Bei-Hu Branch in Taipei, Taiwan.

“First-line treatment strategies should be adapted to resistance patterns on a country-by-country basis … [and] prospective studies are warranted to continuously monitor the prevalence of antibiotic resistance in H. pylori in the Asia-Pacific region,” said Kuo and co-authors.

The systematic review and meta-analysis involved two analyses of studies published between January 1990 and September 2016 – analysis of primary antibiotic resistance (observational studies and RCTs; 176 articles from 24 countries) and analysis of efficacy of first-line H. pylori eradication therapy (RCTs only; 170 articles from 16 countries).

Study participants were adults (aged ≥18 years) diagnosed with H. pylori using a standard diagnostic method, with no history of receiving eradication therapy for H. pylori, and no antibiotic use in the 2 weeks prior to recruitment. 

Primary H. pylori resistance prevalence was most evident for metronidazole (mean prevalence, 44 percent), followed by levofloxacin, clarithromycin, tetracycline, and amoxicillin (mean prevalence, 18, 17, 4, and 3 percent, respectively). [Lancet Gastroenterol Hepatol 2017;doi:10.1016/S2468-1253(17)30219-4]

There was a marked increase in resistance to clarithromycin, metronidazole, and levofloxacin between the years prior to 2000 and 2011–2015 (7 percent to 21 percent for clarithromycin, 36 percent to 45 percent for metronidazole, and 2 percent to 27 percent for levofloxacin), while resistance to amoxicillin and tetracycline did not change drastically over time.

According to the researchers, the increase in clarithromycin resistance could be attributed to the rise in consumption of macrolides, while metronidazole resistance, which was higher in developing countries and lower in countries with higher socioeconomic status, may be linked to the use of this antibiotic for conditions such as parasite infestations or dental infections in developing countries.

Countries with high clarithromycin resistance rates (>20 percent) had a reduced efficacy of clarithromycin-containing H. pylori treatment regimens (<80 percent). Conversely, countries with low clarithromycin resistance (<15 percent) demonstrated higher efficacy of clarithromycin triple therapy (>80 percent).

“These findings collectively suggest that, although clarithromycin-based triple therapy can still be used as the standard first-line treatment in countries where clarithromycin resistance is lower than 15 percent, alternative first-line regimens, such as bismuth quadruple therapy or nonbismuth quadruple therapies, should be considered in countries with high clarithromycin resistance,” said Kuo and co-authors.

The researchers acknowledged the significant heterogeneity between studies, which was influenced by the study regions, periods, resistance-measuring methods, and region-specific infections.

“Our findings provide policy makers with the necessary evidence to decide optimal first-line eradication regimens according to local prevalence of primary antibiotic resistance and develop effective strategies to control the rising antibiotic resistance in their countries,” they said.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Apr 2016
Amiodarone is safe and effective for early junctional ectopic tachycardia prophylaxis in paediatric patients following open heart surgery, based on a study.
Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Jairia Dela Cruz, 05 Mar 2018
Abaloparatide appears to produce significant increases in the bone mass density (BMD), as well as nominal reductions in fractures, in very elderly women with osteoporosis, with a safety profile similar to that in the overall study population, according to a posthoc analysis of the phase III ACTIVE trial.